A new therapeutic target for osteoporosis: Arcyriaflavin A as a CDK4 inhibitor suppressing osteoclastogenesis
Objectives and questions: Macrophage polarization influences osteoclast differentiation, a process regulated by the JAK-STAT3 pathway. CDK4 inhibits this pathway by preventing STAT3 activation. We identified Arcyriaflavin A (ArcyA), an indole-based compound, as a natural CDK4 inhibitor and investigated [for full text, please go to the a.m. URL]
Institutions
- Shanxi Medical University (CN)
- University Hospital Bonn (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Second Hospital of Shanxi Medical University (CN)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2025-10-31
- DOI
- https://doi.org/10.3205/25dkou195
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00